Le medicament du mois. Rosuvastatine (Crestor). ; Drug of the month. Rosuvastatin (Crestor)

peer reviewed ; Rosuvastatin (Crestor) has been recently launched in Belgium by AstraZeneca. This new statin is indicated for the treatment of primary hypercholesterolaemia or combined dyslipidaemia, when changes in dietary habits are insufficient. Direct comparative randomised clinical trials with other statins demonstrated that rosuvastatin exerts a more favourable impact on lipid profile. When compared on a mg basis to other statins, rosuvastatin is associated with a greater reduction in total and LDL cholesterol levels and a greater increase of HDL cholesterol concentration, with a similar... Mehr ...

Verfasser: Scheen, André
Dokumenttyp: journal article
Erscheinungsdatum: 2004
Verlag/Hrsg.: Université de Liège. Revue Médicale de Liège
Schlagwörter: Anticholesteremic Agents/pharmacology/supply & distribution/therapeutic use / Belgium/epidemiology / Cholesterol / HDL/blood/drug effects / LDL/blood/drug effects / Dose-Response Relationship / Drug / Fluorobenzenes/pharmacology/supply & distribution/therapeutic use / Humans / Hypercholesterolemia/blood/drug therapy/epidemiology / Morbidity / Patient Selection / Pyrimidines/pharmacology/supply & distribution/therapeutic use / Randomized Controlled Trials as Topic / Sulfonamides/pharmacology/supply & distribution/therapeutic use / Treatment Outcome / Triglycerides/blood / Human health sciences / Endocrinology / metabolism & nutrition / Pharmacy / pharmacology & toxicology / Sciences de la santé humaine / Endocrinologie / métabolisme & nutrition / Pharmacie / pharmacologie & toxicologie
Sprache: Französisch
Permalink: https://search.fid-benelux.de/Record/base-26584082
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://orbi.uliege.be/handle/2268/10276